Patheon acquires state-of-the-art manufacturing facility from Roche
pharmafile | November 28, 2016 | News story | Manufacturing and Production | Patheon, Roche, South Carolina
Patheon, a provider of drug development and delivery to the pharmaceutical and biopharma sectors, announced that it has acquired a state-of-the-art manufacturing facility from Roche.
The facility is located in Florence, South Carolina, and it had previously looked like Roche would be forced to close the site without being able to find a buyer. Florence County’s Economic Development Partnership executive director Joe W. King was quoted, at the time of talk of Roche closing the facility, that: “I just don’t see them shuttering that nice facility…But sometimes corporate mentality is totally different from the way I think.”
Mr King was proven correct as Patheon stepped in to prevent the complete closure of the facility. The 300,000 square-foot facility on 1,100 acres of land will exchange hands for an “immaterial sum”, as well as the cost of associated inventory and spare parts. Formerly, Roche employed 270 people to work at the plant but it is yet to be seen whether this may change under Patheon’s stewardship.
The company will use the new site to expand its capacity for manufacturing compounds while adding to its manufacturing capabilities globally. As part of the deal, Roche has entered into a multi-year supply arrangement with Patheon. Patheon expects this deal to offset the initial set up cost of the facility.
“As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients,” said James Mullen, CEO of Patheon. “The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”
Ben Hargreaves
Related Content
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …
Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …
